The treatment landscape of acute myeloid leukaemia (AML) is constantly evolving, and a new form of treatment for AML, oral azacitidine, has just become available in Hong Kong. On 18th January 2024, the Hong Kong Society of Haematology organised a scientific symposium to introduce the latest treatment of AML in Hong Kong.
Dr. Law Man Fai, the Chairman of the Hong Kong Society of Haematology, kicked off the event with an opening speech and introduced the speakers. After that, it was honoured to have Dr. Raymond Wong, Honorary Clinical Associate Professor at the Department of Medicine & Therapy of the Chinese University of Hong Kong, discussing the unmet needs in the current AML treatment in Hong Kong and highlighting the plight facing some special populations, especially the elderly.
Following the wonderful presentation by Dr. Wong, Dr. Cristina Papayannidis, Haematology Medical Director at the Institute of Haematology and Medical Oncology in Italy, discussed the therapeutic strategies to maintain remission for AML patients not eligible for transplant and underlined the survival benefit shown in the QUAZAR AML-001 study, which echoed the unmet needs mentioned by Dr. Raymond Wong. Towards the end of the symposium,
Dr. Tony Wu shared some clinical cases involving the use of oral azacitidine in AML treatment. The fruitful, informative symposium was rounded up with a Q&A session, followed by a dinner that facilitated the exchange of clinical experience and expertise.
